Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION		
Name	Name		
ID Number	Specialty		
D.O.B. // MM/DD/YYYY	Address		
Diagnosis	City /State/Zip		
Drug Name Zolgensma	Phone: Fax:		
Dose and Quantity	NPI		
Directions	Contact Person		
Date of Service(s)	Contact Person Phone / Ext.		
STEP 1: DISEASE STATE INFORMATION			
Required Demographic Information: Patient Weight:kg Patient Height:kg Patient Height:ttinches Will the provider be administering the medication to the FEP member within the health plan's geographic service area? ☐ Yes ☐ No If No, a prior authorization is not required through this process. Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic			
service area. If you are not a provider in the geographic se the FEP member's benefit requirements.	rvice area, please contact the health plan for questions regarding		
 Is this member's FEP coverage primary or secondary coverage primary coverage p	this process. Please contact the member's primary coverage for		

	teria Questions: What is the patient's diagnosis? □ Spinal Muscular Atrophy (SMA) □ Other diagnosis (please specify):		
2.	Has the patient had a prior authorization approval for this medica	tion previously? □Yes □No	
3.	Has the diagnosis been confirmed by genetic testing demonstrating bi-allelic mutations in the survival motor neuron 1 (SMN1) gene? ¬Yes ¬No		
4.	Is there deletion of both copies of the SMN1 gene? \square Yes \square No* *If NO, does the patient have compound heterozygous mutations of the SMN1 gene, such as pathogenic variant(s) in both copies of the SMN1 gene or 1 copy and deletion of the second copy of the SMN1 gene? \square Yes \square No		
5.	Is the diagnosis of SMA based on the results of the SMA newbor	n screening? □Yes □No	
6.	Is the baseline anti-adeno-associated virus serotype 9 (AAV9) an	tibody titers less than or equal to 1:50? □Yes □No	
7.	Is there documentation of a genetic test confirming no more than	3 copies of the SMN2 gene? □Yes □No	
8.	Is there documentation of baseline laboratory assessments for the patient's AST, ALT, total bilirubin, and prothrombin time? ☐ Yes ☐ No		
9.	Does the patient have advanced spinal muscular atrophy (e.g., complete paralysis of limbs, permanent ventilator dependence)? ☐ Yes ☐ No		
11.	Is this medication being prescribed by a neurologist, neuromuscular specialist, or pediatrician with expertise in treating SMA? ☐ Yes ☐ No		
12.	Has the patient previously received gene therapy for SMA? □Yes □No		
13.	Will Zolgensma be used in combination with Spinraza (nusinersen) or Evrysdi (risdiplam)? □Yes □No		
	re required for the processing of all requests. Please add any other suppo Coverage will not be provided if the prescribing physician's sig	nature and date are not reflected on this document.	
	pedited review: I certify that applying the standard review time frame may seriously jeopardize the life or healt		
sician's N o 2:	ame Physician Signature ☐ Form Completely Filled Out	Date	
cklist	☐ Provide chart notes	☐ Attach test results	
3:	By Fax: BCBSM Specialty Pharmacy Mailbox	By Mail: BCBSM Specialty Pharmacy Program	

1-877-325-5979

Submit

P.O. Box 312320, Detroit, MI 48231-2320